International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 3, March 2026 ijppr.humanjournals.com ISSN: 2349-7203

Digital Transformation of Regulatory Affairs in Pharmaceutical Quality Assurance: Role of RIM, eCTD and QMS Software Systems

Triveni N. Gore*, Amit J. Gatkal, Neha V. Kamble, Vijaya U. Barge

Department of Pharmaceutical Quality Assurance, PDEA's Shankarrao Ursal College of Pharmaceutical Sciences and Research Centre, Pune, Maharashtra, India. 411014.

Received: 25 January 2026 Revised: 10 February 2026 Accepted: 26 February 2026

ABSTRACT:

The Pharmaceutical industry is experiencing a rapid digital transformation driven by increasing regulatory complication, globalization of drug development and high expectations for data integrity. Regulatory Affairs and Quality Assurance functions play a critical role in ensuring that pharmaceutical products consistently meet regulatory and quality requirements. Traditionally these functions relied on manual, paper- based systems which are susceptible to inefficiencies and compliance risks. This review comprehensively examines the digital transformation of regulatory affairs within a pharmaceutical Quality Assurance framework. These emphasis on Regulatory Information Management (RIM) systems, electronic Common Technical Document (eCTD) submission tools and Quality Management System (QMS) software. The review discusses the regulatory drivers supporting digitalization, the functional role of key software platforms and integration of RA and QA through digital environment. Additionally, the role of digital tools in ensuring data integrity, inspection readiness and lifecycle compliance is highlighted. This comprehensive approach provides a novel and industry knowledge of how digital regulatory tools enhance pharmaceutical quality, compliance and operational efficiency.

Keywords: Digital regulatory affairs; Pharmaceutical quality assurance; RIM systems; eCTD; QMS software; Data integrity

1. INTRODUCTION:

The pharmaceutical industry is one of the most regulated sectors in the world. It requires strict overview to ensure product quality, efficacy and safety. Regulatory affairs and quality assurance have traditionally depended on manual documentation, separate systems and paper submissions. However, increased global regulatory complexity, data volume and market pressures have pushed for a digital transformation. As a result, advanced software systems like RIM, eCTD and QMS have become essential for modern regulatory operations and quality strategy. [1]

The increasing complications of global pharmaceutical regulation has made it necessary to shift from document-centric processes to data-driven regulatory ecosystems. Recent literature shows that digital transformation in regulatory affairs is no longer limited to electronic submission formats. It now includes integrated platforms that support lifecycle management, regulatory intelligence and quality compliance.[2]

As multinational pharmaceutical companies handle multiple submissions in various regions, structured data governance and real-time regulatory visibility have become crucial. The introduction of the electronic Common Technical Document (eCTD) has greatly improved the global standardization of submission structures. However, researchers note that the eCTD mainly serves as a standardized technical submission format rather than a complete regulatory management system. [3]

While it improves review efficiency and consistency, the eCTD does not provide centralized oversight of regulatory commitments, tracking of product registrations across markets. To address these shortcomings, Regulatory Information Management (RIM) systems have emerged as strategic solutions that integrate regulatory data throughout the product lifecycle. Research indicates that RIM systems improve operational transparency, shorten submission cycle times and support global regulatory strategies by merging fragmented databases into cohesive digital platforms.[4]

Additionally, linking of RIM with Quality Management Systems (QMS) is a game- changer. It improves the connection between regulatory submissions and quality events such as deviations, change controls and corrective and preventive actions (CAPA), thus

enhancing compliance readiness. From a Quality Assurance viewpoint, digital regulatory systems significantly contribute to data integrity and inspection readiness. Recent studies emphasize that electronic records need to be traceable, clearly attributable and regularly updated to meet regulatory audit standards. [5]

Newer regulatory software powered by automation and AI makes dossier compilation, metadata tagging and validation smoother. This cuts down manual mistakes and boosts submission accuracy. [4]

The use of real-world evidence (RWE) and digital health data in regulatory decision-making is on the rise. This has created a growing need for flexible digital infrastructures that can handled structured data analysis. [2]

This evolution indicates a broader shift toward predictive regulatory planning and risk-based quality management. Despite these benefits, studies consistently point out implementation challenges, including high infrastructure costs, cybersecurity risks, complicated system validation and resistance to change within organizations. Successful digital transformation in regulatory affairs requires strategic governance and integration across departments. It also needs to align with pharmaceutical Quality Assurance frameworks to ensure ongoing regulatory compliance and operational excellence.[3]



Figure 1. Digital Transformation

2. Literature Review and Conceptual Framework

2.1 Digital Transformation in Pharmaceuticals

Digital Transformation in Pharmaceuticals Research emphasizes that digital transformation boosts operational efficiency and regulatory compliance in life science organizations. It uses technologies like cloud computing, big data analytics, AI and automation to enhance process quality and support decision-making.[6]

Pharmaceutical companies are digitizing Quality Management Systems to improve traceability, data integrity and continuous quality improvement. They are also integrating regulatory content and processes within unified digital platforms. [1]

Recent literature shows that digital transformation in the pharmaceutical industry goes beyond simply digitizing operations. It represents a strategic shift toward integrated, data-focused business models. Studies reveal that technologies such as cloud computing, artificial intelligence, big data analytics and process automation improve regulatory compliance. This tech advancements also boosts decision-making and organizational flexibility. [6]

Recent findings indicate that digital transformation in pharmaceutical regulatory affairs is closely linked to overall digital maturity and data standardization initiatives. This digitalization enhances synchronization of cross-border submissions and improves global product lifecycle oversight through centralized data architectures, reducing duplication errors and improving submission accuracy across different regulatory areas. [7]

Additionally, the authors point out the significance of cloud-based regulatory platforms in enabling collaborative submission development among geographically distributed regulatory teams. Cloud-enabled systems improve version control, maintain consistent metadata and allow secure document sharing, thereby reducing compliance risks during inspections. Another emerging

perspective is the use of digital twins and advanced analytics in regulatory and quality oversight. Predictive analytics tools can support risk-based regulatory strategies by identifying potential compliance issues prior to formal submission.[8][9]

This proactive approach aligns with modern regulatory expectations for ongoing quality monitoring and real-time oversight. The literature also provides a widely accepted theoretical framework describing digital transformation as an organizational change process involving technology adoption, process redesign and value creation. Applying this framework to pharmaceutical regulatory affairs shows that effectively implementing RIM and eCTD systems requires restructuring organizations, developing capabilities and aligning leadership rather than simply installing new technology.[10]

2.2 Regulatory Affairs Automation

Regulatory Affairs Automation Studies detail automation tools in regulatory operations, including Regulatory Information Management systems, document management systems, analytics and publishing tools like eCTD submission engines. Automation simplifies tasks and reduces human workload, allowing for quicker dossier preparation and compliance monitoring. [11]

Beyond basic automation tools, recent literature describes regulatory affairs automation as a shift toward intelligent workflow balance and integrated regulatory ecosystems. Rather than just focusing on document management and eCTD publishing engines, modern automation strategies emphasize structured data repositories, automated metadata generation and cross-platform comparability.[12]

These systems reduce overflows in dossier preparation and enable dynamic tracking across multiple global regulatory authorities. Scholarly discussions also highlight the increasing use of robotic process automation (RPA) within regulatory operations. RPA tools automate repetitive regulatory tasks like document formatting, hyperlink validation, data entry and tracking submissions to health authorities. This minimizes manual errors and improves operational consistency.[13]

The use of RPA is particularly valuable in variation management and periodic safety update reporting, where high volumes of documentation raise the likelihood of human errors. Additionally, cloud-based regulatory automation platforms enhance collaboration between global regulatory teams and affiliate offices. Centralized cloud infrastructures improve real-time sharing of regulatory intelligence, ensure controlled version management and strengthen audit readiness. These platforms integrate structured regulatory databases that include labeling updates, submission milestones and post-approval commitments into unified dashboards. [14]

Artificial intelligence (AI) is becoming more integrated into regulatory automation frameworks. AI-enabled natural language processing (NLP) tools help with automated content extraction, monitoring regulatory intelligence and classifying health authority inquiries. These capabilities enhance submission preparedness and enable predictive risk assessment in regulatory planning. However, the literature warns that ensuring algorithm transparency and validation controls is crucial to maintain regulatory acceptance and compliance with electronic record standards. [15]

3. Regulatory Information Management (RIM) Systems

3.1 Definition and Role

RIM systems are integrated digital platforms meant to centralize, structure, and manage regulatory data across the entire product lifecycle. Unlike traditional document storage systems, RIM solutions function as strategic data governance tools, coordinating submission planning, regulatory tracking, communication with health authorities and lifecycle maintenance across global markets. RIM systems serve as the "single source of truth" for regulatory metadata, ensuring consistency between dossiers, labeling, manufacturing changes and post-approval variations. By consolidating structured regulatory data, organizations enhance transparency, reduce duplication and strengthen regulatory intelligence capabilities.[2] [11]

Modern RIM platforms typically support:

• End-to-end submission planning and tracking

• Centralized regulatory data repositories

• Automated monitoring of milestones and deadlines

• Logging communications with health authorities

• Version control and electronic audit trails

• Assessments of regulatory impacts for product changes

Structured RIM environments shift regulatory operations from reactive documentation management to proactive compliance governance. Real-time dashboards allow regulatory teams to efficiently track global product registrations, variation timelines and renewal deadlines. Moreover, RIM systems improve inspection readiness by keeping traceable records that comply with electronic record regulations (e.g., 21 CFR Part 11 compliance principles). Adopting centralized regulatory data models enhances consistency between regional affiliates and headquarters, which improves harmonization for global submission. [16] [17]

3.2 Integration with Enterprise Systems

RIM systems do not work alone; their effectiveness relies on smooth integration with other enterprise platforms. Modern pharmaceutical environments need interoperability among Regulatory Affairs, Quality Assurance, Clinical Operations and Manufacturing systems. Integration promotes synchronized data governance and minimizes inconsistencies in regulatory submissions and operational records.

Typically, RIM systems connect with:

- Quality Management Systems (QMS) for tracking deviations, linking CAPA and assessing change control impacts.
- Enterprise Resource Planning (ERP) systems for data related to manufacturing sites, product codes and supply chain updates.
- Clinical Trial Management Systems (CTMS) for registering investigational products and obtaining trial approvals.
- Electronic Document Management Systems (eDMS) for controlling documentation workflows. [4]

This interoperability reduces manual data entry and prevents duplication across departments. For instance, when a manufacturing change is noted in QMS, integrated RIM systems can automatically trigger regulatory impact assessments and variation submissions. Cloud-based enterprise architectures further enhance integration by allowing centralized data exchange through APIs and standardized data models. Such integration improves data integrity, boosts audit readiness and ensures consistent global regulatory reporting.

Digital integration also facilitates advanced analytics, enabling organizations to predict submission timelines, assess regulatory risks and optimize lifecycle strategies. As regulatory requirements become more complex across regions, enterprise integration ensures that regulatory commitments align with operational execution.[14]

4. Electronic Common Technical Document (eCTD)

4.1 Overview of eCTD

eCTD is the standardized electronic submission format used for regulatory applications across major health authorities. Developed under the International Council for Harmonization (ICH), eCTD provides a modular structure for the electronic submission, review and lifecycle management of medicinal product dossiers.

The eCTD structure consists of five modules: administrative information (Module 1, region-specific), summaries (Module 2), quality documentation (Module 3), non-clinical study reports (Module 4),and clinical study reports (Module 5). Unlike the traditional paper-based CTD, eCTD uses an XML backbone that allows for metadata tagging, document organization and lifecycle management through sequence tracking. [18]

The XML-based design of eCTD enables automated technical checks before submission, ensuring hyperlink integrity, document completeness and correct placement within the dossier. This reduces technical rejection rates and improves the consistency of submission quality across regulatory regions. A major strength of eCTD is its lifecycle management capability. [19]

Each submission is a "sequence," allowing for additions, replacements, or deletions of documents without needing to resubmit the entire dossier. This structured lifecycle approach promotes regulatory transparency and traceability during variations, renewals and post-approval changes.[20]

The global adoption of eCTD has greatly decreased administrative burdens and improved harmonization among agencies such as the U.S. FDA, European Medicines Agency (EMA), PMDA (Japan) and Health Canada. The shift to eCTD version 4.0 enhances structured data submission by transitioning from document-centric to data-centric regulatory frameworks, improving machine readability and regulatory analytics.[18]

4.2 Importance of eCTD in Quality Assurance

Importance of eCTD in Quality Assurance Implementing eCTD significantly boosts quality assurance in regulatory submissions by introducing structured validation, traceability and version control. Unlike preparing dossiers manually, eCTD features automated validation tools that identify structural issues, broken links, missing files and metadata errors before submission. From a quality systems viewpoint, eCTD strengthens document control by maintaining complete audit trails for all submission sequences. Each change to a dossier is recorded within the lifecycle management framework, ensuring traceability and compliance with electronic records regulations like 21 CFR Part 11.[20]

Structured electronic submissions reduce variability between regional filings. By enabling content reuse and standardized formatting, eCTD lessens discrepancies in how technical data is presented, which improves review efficiency and reduces regulatory queries. [19]

Recent analyses show that agencies using advanced eCTD review tools experience quicker dossier navigation, improved cross-referencing, and better risk-based assessment capabilities. These enhancements contribute to faster review times and overall regulatory performance. [21]

However, successful implementation requires trained regulatory professionals, validated publishing software and strong internal quality checks. Without proper governance, technical validation errors may still happen despite electronic systems.[19]

5. Quality Management Systems (QMS)

5.1 Digital QMS Fundamentals

Quality Management Systems in pharmaceutical organizations combine quality processes such as:

- CAPA (Corrective and Preventive Actions)
- Deviation and audit management
- Document control and approval workflows
- Training and compliance records

Digital QMS tools automate these processes, ensuring consistency, reducing manual errors and meeting data integrity needs.[22]

Digital Quality Management Systems (QMS) in pharmaceutical manufacturing bring together quality processes like CAPA, deviation handling and change management. These systems also cover audit tracking, document control and training records- all in one electronic platform. Research indicates that digital integration enhances process transparency, reduces documentation cycle time and improves communication in regulated environments. By centralizing data, organizations achieve better tracking and oversight of quality events. [23]

Electronic QMS solutions also enhance data reliability and operational efficiency by automating workflows, implementing role-based approvals and maintaining secure audit trails. Studies show that automation reduces human error in documentation and significantly boosts data integrity performance in GMP-regulated facilities. Digital document management further improves version control and retrieval accuracy during inspections. [24]

5.2 Impact on Regulatory Compliance

Adopting digital QMS platforms is linked to better inspection readiness and compliance performance. Analyses of pharmaceutical firms implementing electronic quality systems show measurable reductions in audit findings and quicker CAPA closure timelines.

Real-time dashboards and quality analytics allow for early detection of non-conformities, promoting proactive fixes instead of reactive corrections.[25]

Additionally, digital QMS enhances risk-based decision-making by using trend analysis and structured data reporting. Scholarly reviews indicate that integrating analytics into QMS frameworks supports predictive quality management, reduces the recurrence of deviations and strengthens long-term regulatory confidence. These systems directly contribute to a culture of continuous improvement in pharmaceutical operations.[26]

6. Integration and Synergy Across RIM, eCTD, and QMS

6.1 Unified Quality and Regulatory Approach

Quality Management Systems (QMS) creates a connected digital environment. This environment links regulatory submissions with quality data throughout the product lifecycle. Research shows that harmonized regulatory and quality data exchange improves lifecycle oversight, reduces information silos, and enhances consistency in submission documents and post-approval maintenance. This combined approach allows for traceability from development to commercialization and variation management. [27]

Integrated platforms let regulatory teams access deviation records, CAPA outcomes, change controls and audit histories directly while preparing submissions or managing post-approval variations. Studies in the pharmaceutical digital landscape show that this integration significantly cuts down on document reconciliation errors and submission delays. Sharing data in real time between quality and regulatory departments improves the accuracy of Module 3 updates and boosts regulatory credibility. [28]

In addition, digital compatibility between RIM and QMS systems enhances governance by connecting regulatory commitments with internal quality actions. Reviews suggest that organizations using integrated regulatory and quality databases have better inspection results due to the immediate availability of compliance history and organized audit trails. This clear visibility aids proactive lifecycle management and lowers compliance risks. [29]

6.2 Benefits of Digital Integration

One significant benefit of integrating RIM, eCTD, and QMS platforms is the automation of manual processes that have traditionally been part of regulatory documentation and quality event tracking. Research shows that automation reduces administrative workload, shortens submission preparation times and cuts down on duplication of effort across departments. Automating workflows also makes reviews more efficient and lowers the chance of human transcription errors.[30]

Another important benefit is creating a “single source of truth,” where regulatory and quality data are stored in linked systems. Studies on enterprise-wide pharmaceutical IT integration show that unified databases improve data consistency, prevent version conflicts and ensure that approved dossiers match manufacturing practices. This shared data setup increases organizational transparency and regulatory confidence. [31]

Improved traceability and audit readiness are also key results of digital integration. Studies on inspection results indicate that companies with integrated quality-regulatory systems respond to audits faster due to centralized access to submission records, change controls and CAPA documentation. Well-organized metadata and searchable electronic repositories significantly boost inspection readiness and documentation accuracy.[32]

Furthermore, digital integration promotes global standardization of regulatory and quality processes in multinational pharmaceutical operations. Literature on global compliance management highlights that connected digital platforms support standardized workflows, consistent documentation templates and synchronized variation management across various regulatory areas. This consistency reduces operational differences and helps align global regulatory strategies.[33]

Finally, a unified digital ecosystem facilitates strategic regulatory planning and ongoing quality improvement. By using analytics, monitoring trends and employing predictive compliance tools, organizations can anticipate regulatory risks and make better lifecycle management decisions. Discussions stress that digital integration strengthens regulatory resilience, enhances operational efficiency and supports sustainable compliance in complex pharmaceutical markets. [34]

7. Challenges of Implementation

7.1 Technical Challenges

One major technical challenge is integrating legacy systems with modern digital platforms. Research shows that pharmaceutical companies often face data incompatibility, inconsistent metadata structures and limited API connectivity during system migration. These issues make it harder to synchronize regulatory and quality databases, which increases the risk of data duplication and compliance gaps. [29]

Data migration and standardization across organizational silos also complicate digital QMS implementation. Case studies show that historical GMP records often exist in various formats. This situation requires extensive cleansing, validation and mapping before they can be integrated into unified systems. Poorly managed migration processes can compromise data integrity and audit traceability. [32]

System validation under regulatory compliance requirements remains a critical challenge. Discussions on computerized system validation highlight that digital platforms must undergo thorough risk-based validation, which includes installation qualification (IQ), operational qualification (OQ) and performance qualification (PQ). Maintaining system control while implementing updates or patches raises resource demands and increases technical oversight requirements. [28]

7.2 Organizational and Cultural Challenges

Beyond technical barriers, resistance within organizations greatly affects digital transformation outcomes. Research in pharmaceutical operations management shows that employee reluctance, low digital literacy and fear of workflow disruption can slow down the adoption of integrated regulatory and quality systems. Successful implementation requires structured change management strategies and active engagement from leadership. [34]

Collaboration between regulatory affairs, quality assurance, IT and manufacturing teams is also critical. Studies on enterprise digital transformation reveal that isolated departmental structures hinder information sharing and reduce the effectiveness of integrated compliance systems. Building a collaborative digital culture improves user acceptance and system use.[27]

8. Emerging Trends and Future Directions

Digitalization in pharmaceutical regulatory and quality systems continues to progress with rapid technological advancements. Emerging technologies like artificial intelligence (AI), advanced analytics and distributed ledger systems are being explored. They're aimed at boosting compliance oversight, predictive risk management and supply chain transparency. These innovations aim to shift organizations from reactive compliance models to predictive and data-driven regulatory strategies. [30]

8.1 AI and Advanced Analytics

Artificial intelligence and machine learning applications are becoming more common in regulatory intelligence and quality analytics. Research suggests that AI-driven tools can analyze historical inspection findings, deviation trends and submission patterns to predict potential compliance risks. Predictive analytics enhances decision-making by identifying recurring non-conformances before they escalate into regulatory observations. [31]

Advanced analytics also aid in automated document classification and metadata tagging within eCTD systems. This improvement boosts submission accuracy and review efficiency. Studies show that AI-enabled natural language processing can streamline regulatory dossier compilation and reduce the time needed for human review.[35]

8.2 Blockchain for Traceability

Blockchain technology has emerged as a promising solution for boosting traceability and data integrity across pharmaceutical supply chains. Research indicates that distributed ledger systems provide tamper-resistant documentation, ensuring secure tracking of regulatory submissions, batch records and quality events. This technology enhances transparency and reduces risks related to replication and data manipulation. [36]

Integrating blockchain with QMS and regulatory systems could enable real-time verification of manufacturing and distribution records. Analyses suggest that decentralized validation frameworks may strengthen trust among regulators, manufacturers and supply chain stakeholders. [37]

8.3 Regulatory Expectations

Future regulatory expectations will likely focus on digital maturity, real-time data access and increased transparency. Discussions on regulatory innovation indicate that agencies will value structured data submissions and advanced monitoring capabilities. Organizations embracing integrated digital ecosystems will be better prepared to meet changing compliance standards and global harmonization efforts.[38]

9. Conclusion

The digital transformation of regulatory affairs and quality management in the pharmaceutical industry represents a clear shift toward integrated, intelligence-based compliance systems. This paper has shown that Regulatory Information Management (RIM), electronic Common Technical Document (eCTD) and Quality Management Systems (QMS) work best when used within a single digital environment. Together, these systems support structured data management, clear visibility into processes and smooth interaction between regulatory submissions and quality operations.

However, challenges like integrating old systems, moving data, validation issues and resistance from within the organization can make implementation difficult. Still, adopting digital strategies can lead to noticeable improvements in efficiency, audit readiness, traceability and risk reduction. Additionally, the rise of artificial intelligence, data analysis and blockchain technology marks a move from reactive compliance approaches to more proactive, data-focused regulatory management.

In a complicated global regulatory landscape, combining RIM, eCTD and QMS is necessary, not optional. Organizations that embrace this combination will improve their regulatory strength, boost product quality and maintain a competitive edge in the changing pharmaceutical market.

Acknowledgement: Authors are Thankful to PDEA's Shankarrao Ursal College of Pharmaceutical Sciences and Research Centre, Pune.

Disclosure of conflict of interest: The Authors declare no conflict of interest.

REFERENCES:

1. Ullagaddi P. Digital transformation in the pharmaceutical industry: enhancing quality management systems and regulatory compliance. Int J Health Sci. 2024; 12:2372-5079. doi:10.15640/ijhs. v12n1a4.
2. Arlett P, Kjær J, Broich K, Cooke E. Real-world data and real-world evidence in regulatory decision-making. Clin Pharmacol Ther. 2021;109(4):843-850. doi:10.1002/cpt.2011.
3. Neeley J, Borror C. Regulatory submission modernization and digital transformation in the pharmaceutical industry. Ther Innov Regul Sci. 2020;54(6):1340-1348. doi:10.1007/s43441-020-00187-9.
4. Kumar R, Singh V. Digital transformation in pharmaceutical regulatory operations: emerging technologies and compliance perspectives. J Pharm Innov. 2023. Available from: https://link.springer.com/article/10.1007/s12247-023-09650-0
5. Saha S, Bhattacharya S. Data integrity in pharmaceutical quality systems: challenges and digital solutions. J Pharm Qual Assur. 2022;8(2):55-63.
6. Miozza M, Brunetta F, Appio FP. Digital transformation of the pharmaceutical industry: a future research agenda for management studies. Technol Forecast Soc Change. 2024; 207:123580. doi: 10.1016/j.techfore.2024.123580.
7. Trotta A, Garengo P, Sardi A. Digital transformation and performance measurement in regulated industries. Technol Forecast Soc Change. 2023. doi: 10.1016/j.techfore.2023.122156.
8. O'Connor Y, Yang Y. Digital transformation in highly regulated environments: evidence from life sciences. Inf Syst Front. 2022. doi:10.1007/s10796-021-10185-0.
9. Bresciani S, Ferraris A, Del Giudice M. The role of digital transformation in fostering innovation in pharmaceutical firms. Technovation. 2022; 119:102421. doi: 10.1016/j.technovation.2022.102421.
10. Vial G. Understanding digital transformation: a review and research agenda. J Strateg Inf Syst. 2019;28(2):118-144. doi: 10.1016/j.jsis.2019.01.003.
11. Chandrasekaran K, Pramod Kumar TM, Balamuralidhara V. The regulatory affairs automation tools used in the pharmaceutical industry: an overview. Int J Drug Regul Aff. 2024;12(1):36-39. Available from: https://www.ijdra.com/index.php/journal/article/view/649 doi: 10.22270/ijdra.vl2il.649
12. Haug CJ, Drazen JM. Artificial intelligence and regulatory decision-making in medicine. N Engl J Med. 2021;385(21):1931-1934. doi:10.1056/NEJMp2111553.
13. Syed R, Suriadi S, Adams M, Bandara W, Leemans M, Ouyang C, et al. Robotic process automation: contemporary themes and challenges. Comput Ind. 2020; 115:103162. doi: 10.1016/j.compind.2019.103162.

14. Agrawal R, Choudhary A, De S. Cloud computing adoption in regulated industries: implications for compliance and governance. Inf Syst Front. 2022. doi:10.1007/s10796-021-10210-2.
15. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug development and regulatory processes. Drug Discov Today. 2021;26(1):80-93. doi: 10.1016/j.drudis.2020.09.010.
16. Yogesh Rabadiya, Jignasha Dabhi, Sanjay Chauhan, An Overview of Regulatory Management Software for Educational and Industrial Sectors, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 2, 898-913. https://doi.org/10.5281/zenodo.14862201
17. Muehlbacher, A. C., & Kaczmarek, M. (2020). Making regulatory decisions transparent and structured. Frontiers in Medicine, 7, 559. https://doi.org/10.3389/fmed.2020.00559
18. International Council for Harmonisation (ICH). (2022). eCTD v4.0 Implementation Guide. https://www.ich.org
19. Tholeti, S., Reddy, P., & Kumar, M. (2020). Evolution and implementation challenges of electronic Common Technical Document submissions. Therapeutic Innovation & Regulatory Science, 54(5), 1023–1031. https://doi.org/10.1007/s43441-020-00174-6
20. Patterson, S., & Hester, J. (2019). Lifecycle management in electronic regulatory submissions: Improving efficiency and compliance. Regulatory Affairs Journal, 30(4), 215–222.
21. Ramakrishna, V., & Bhattacharya, S. (2021). Digital transformation in regulatory review processes. Journal of Pharmaceutical Policy and Practice, 14(1), 45. https://doi.org/10.1186/s40545-021-00323-5
22. Pharma QMS Implementation Guide: From Paper-Based to Digital Quality Systems - Emedicodiary
23. Souza B, et al. Digital transformation in pharmaceutical quality systems. J Pharm Innov. 2021.
24. Khinast J, O'Sullivan C. Data integrity and digitalization in the pharmaceutical industry. Pharm Eng. 2019.
25. Haddad A, et al. Impact of digital quality management systems on GMP compliance performance. Int J Pharm. 2020.
26. Rathore AS, Winkle H. Quality by design and digital enablement in pharmaceutical manufacturing. J Valid Technol. 2018.
27. Sultana J, et al. Digital transformation in regulatory affairs and lifecycle management. Ther Innov Regul Sci. 2021.
28. McDowell RD. Electronic regulatory submissions and data integrity in the pharmaceutical industry. J GXP Compliance. 2019.
29. van Trieste L, Baesens B. Digitization and compliance risk management in pharmaceutical operations. Comput Ind. 2020.
30. Ponsar H, et al. Automation and digitalization in pharmaceutical regulatory processes. Int J Pharm. 2020.
31. Khinast J, et al. Digital pharmaceutical manufacturing and integrated information systems. Eur J Pharm Sci. 2019.
32. Al-Tabbaa O, et al. Digital documentation systems and inspection readiness in pharmaceutical manufacturing. J Pharm Innov. 2021.
33. Haug A, et al. Enterprise system integration and process standardization in regulated industries. Inf Syst Front. 2018.
34. Attaran M. Digital technology and business process transformation in highly regulated industries. Bus Horiz. 2020.
35. Rathore AS, et al. Digital enablement and advanced analytics in pharmaceutical quality systems. J Pharm Innov. 2021.
36. Casino F, Dasaklis TK, Patsakis C. A systematic literature review of blockchain-based applications. Telemat Inform. 2019;36:55-81. doi:10.1016/j.tele.2018.11.006.
37. Saberi S, Kouhizadeh M, Sarkis J, Shen L. Blockchain technology and its relationships to sustainable supply chain management. Int J Prod Res. 2019;57(7):2117-2135.
38. van Boxtel C, et al. Regulatory innovation and digital transformation in pharmaceutical governance. Drug Discov Today. 2020.

How to cite this article:
Triveni N. Gore et al. Ijppr.Human, 2026; Vol. 32 (3): 369-377.

Conflict of Interest Statement: All authors have nothing else to disclose.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.